Article
MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Dec 2022
Fenor María Dolores, Ruiz-Llorente Sergio, Rodríguez-Moreno Juan Francisco, Caleiras Eduardo, Torrego Juan Carlos, Sevillano-Fernández Elena, Navarro Paloma, Yagüe-Fernández Mónica, Amarilla-Quintana Sandra, Barquín Arantzazu, García-Donas Jesús
Abstract excerpt
PURPOSE: The identification of subpopulations harboring druggable targets has become a major step forward in the subclassification of solid tumors into small groups suitable for specific therapies. BRAF fusions represent a paradigm of uncommon and targetable oncogenic events and have been widely correlated to the development of specific malignancies. However, they are only present in a limited frequency across...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.